## Andrew H S Lee

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8376339/publications.pdf

Version: 2024-02-01

35 2,826 21 papers citations h-index

h-index g-index

36 3305
times ranked citing authors

395702

33

36 all docs 36 docs citations

#	Article	IF	Citations
1	Prognostic markers in tripleâ€negative breast cancer. Cancer, 2007, 109, 25-32.	4.1	1,091
2	Updated UK Recommendations for HER2 assessment in breast cancer. Journal of Clinical Pathology, 2015, 68, 93-99.	2.0	203
3	An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Human Pathology, 2003, 34, 1009-1015.	2.0	163
4	The histological diagnosis of metastases to the breast from extramammary malignancies. Journal of Clinical Pathology, 2006, 60, 1333-1341.	2.0	159
5	Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast. Histopathology, 2007, 51, 336-344.	2.9	128
6	Correlation of Histologic Prognostic Factors in Core Biopsies and Therapeutic Excisions of Invasive Breast Carcinoma. American Journal of Surgical Pathology, 2003, 27, 11-15.	3.7	127
7	$\hat{l}^2$ -catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Modern Pathology, 2010, 23, 1438-1448.	5.5	111
8	Why is carcinoma of the breast more frequent in the upper outer quadrant? A case series based on needle core biopsy diagnoses. Breast, 2005, 14, 151-152.	2.2	76
9	The Nottingham Prognostic Index for Invasive Carcinoma of the Breast. Pathology and Oncology Research, 2008, 14, 113-115.	1.9	73
10	The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 473-479.	2.8	72
11	The updated <scp>ASCO</scp> / <scp>CAP</scp> guideline recommendations for <scp>HER</scp> 2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. Histopathology, 2014, 64, 609-615.	2.9	68
12	The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. Journal of Clinical Pathology, 2006, 60, 299-302.	2.0	65
13	Immunoprofile of metaplastic carcinomas of the breast. Histopathology, 2017, 70, 975-985.	2.9	57
14	An approach to the diagnosis of spindle cell lesions of the breast. Histopathology, 2016, 68, 33-44.	2.9	50
15	Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast. Histopathology, 2012, 60, 880-884.	2.9	41
16	The expression of Wilms' tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast. Histopathology, 2007, 51, 824-828.	2.9	39
17	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. Histopathology, 2016, 68, 45-56.	2.9	37
18	National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1301-1302.	1.6	35

#	Article	IF	CITATIONS
19	Use of immunohistochemistry in the diagnosis of problematic breast lesions. Journal of Clinical Pathology, 2013, 66, 471-477.	2.0	34
20	Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification: Table 1. Journal of Clinical Pathology, 2011, 64, 490-492.	2.0	30
21	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. British Journal of Cancer, 2019, 120, 1075-1082.	6.4	27
22	Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. Histopathology, 2017, 70, 632-642.	2.9	22
23	Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis). European Journal of Cancer, 2009, 45, 1162-1167.	2.8	21
24	The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation. Journal of Clinical Pathology, 2014, 67, 573-575.	2.0	20
25	Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies. Histopathology, 2020, 77, 303-313.	2.9	19
26	Pleomorphic adenomaâ€like tumour of the breast. Histopathology, 2016, 68, 405-410.	2.9	15
27	Effectiveness of percutaneous vacuum-assisted excision (VAE) of breast lesions of uncertain malignant potential (B3 lesions) as an alternative to open surgical biopsy. European Radiology, 2021, 31, 9540-9547.	4.5	13
28	The value of examination of multiple levels of mammary needle core biopsy specimens taken for investigation of lesions other than calcification. Journal of Clinical Pathology, 2012, 65, 1097-1099.	2.0	8
29	Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?. Histopathology, 2016, 69, 20-24.	2.9	8
30	Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast. Histopathology, 2021, 78, 871-881.	2.9	5
31	Malignant phyllodes tumour of the breast mimicking endometriosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1051-1053.	2.8	3
32	Angiosarcoma arising in the capsule of a mammary silicone implant. Diagnostic Cytopathology, 2022, 50, .	1.0	3
33	Brief Fixation and Hormone Receptor Expression in Breast Cancer. American Journal of Surgical Pathology, 2015, 39, 425.	3.7	0
34	Evidence that neoadjuvant anthracycline based combination chemotherapy (NACT) in breast cancer (BC) induces phenotypical changes which guides the optimal adjuvant therapy Journal of Clinical Oncology, 2019, 37, 590-590.	1.6	0
35	The frequency of HER2 amplification and the percentage of membrane staining in HER2 2 + invasive carcinomas of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 0, , .	2.8	0

3